“All In” For a Huge Pot: The PROWESS-SHOCK Trial for Refractory Septic Shock
- 1 October 2007
- journal article
- Published by Mary Ann Liebert Inc in Surgical Infections
- Vol. 8 (5) , 491-494
- https://doi.org/10.1089/sur.2007.9980
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: Analysis of efficacy and safety data in a large surgical cohortSurgery, 2007
- Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trialThe Lancet, 2007
- Can we RESOLVE the treatment of sepsis?The Lancet, 2007
- An Opinion Too Far—The Campaign Against the Surviving Sepsis CampaignSurgical Infections, 2006
- Activated protein C (Xigris®) treatment in sepsis: a drug in troubleActa Anaesthesiologica Scandinavica, 2006
- Drotrecogin Alfa (Activated) in Severe SepsisNew England Journal of Medicine, 2006
- Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of DeathNew England Journal of Medicine, 2005
- Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsisThe American Journal of Surgery, 2004
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001